GLP1R and type 2 diabetes mellitus: Furthermore, we introduced the clinically used T2DM treatment GLP1-R peptide agonist, semaglutide, to directly compare with exendin-4 to show that the effects of receptor activation on cellular mechanisms are conserved between different agonists.